Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380575 · ClinicalTrials.gov registry record · Phase 3
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
A Phase 3 study of Hyponatremia, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT00380575: Completed Phase 3 study of Hyponatremia, sponsored by Cumberland Pharmaceuticals.
NCT00380575 is a Phase 3 study of Hyponatremia that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 84 participants, below the 310-participant average among 3 other Hyponatremia trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00380575, a Phase 3 study of Hyponatremia, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
Conditions Studied
Interventions
- DRUG YM087
Study Locations (20)
California
- - La Jolla
- - Los Angeles
- - Santa Rosa
Arizona
- - Phoenix
- - Tuscon
Florida
- - Miami
- - Plantation
Missouri
- - Rolla
- - St Louis
Alabama
- - Mobile
Illinois
- - Springfield
Indiana
- - Indianapolis
Louisiana
- - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2000-08 |
| Est. Completion | 2003-02 |
| Phase | Phase 3 |
What the finished NCT00380575 record still lists
NCT00380575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 310-participant average among 3 other Hyponatremia trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Hyponatremia appearing as the primary indexed condition, and to 1 intervention - of which YM087 is the first listed.
NCT00380575 names 20 study sites across 15 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00380575 about?
NCT00380575 is a clinical study titled "Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia". This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
What is the current status of trial NCT00380575?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2000-08. Estimated completion is 2003-02.
What conditions does trial NCT00380575 study?
This clinical trial studies the following conditions: Hyponatremia.
What interventions are being tested in trial NCT00380575?
The interventions under investigation include: YM087 (DRUG).
Who is sponsoring clinical trial NCT00380575?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00380575 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyponatremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia
COMPLETED · Phase 3
-
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation
COMPLETED · Phase 3
-
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia